Evangelos AktoudianakisAesop ChoMichael GraupeLateshkumar Thakorlal LadPaulo A. Machicao TelloJonathan William MedleySamuel E. MetoboDevan NaduthambiBarton W. PhillipsScott Preston Simonovich
Finally, current and future challenges in the application of PD-1 and PD-L1 inhibitors are discussed with emphasis on the role of predictive biomarkers. Introduction Over the years, an improved understanding of the molecular mechanisms underlying immune regulation has led to the redirection of ...
Programmed death receptor-1 [programmed cell death protein 1 (PD-1)] and programmed death protein ligand-1 [programmed death-ligand 1 (PD-L1)] inhibitors, have improved tumor therapy in cancer immunotherapy (1). The combination of PD-1 and PD-L1 inhibits the activity of T cells and act ...
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. Oncoimmunology. 2016;5:e1254856. doi:10.1080/2162402X.2016.1254856. PMID:28123899Jelinek, T.; Hajek, R. PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. Oncoimmunology 2016, 5, e1254856. [Cross...
非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识 01 引言 近年来,以程序性死亡受体1(programmed death-1, PD-1)/PD配体1(PD ligand 1, PD-L1)免疫检查点抑制剂为主的免疫治疗在晚期肺癌中取得了突破性的进展,改变了该领域的治疗...
Since the discovery of immune checkpoint proteins, there has been a special interest in developing antibodies that block programmed cell death 1 receptor (PD-1) and programmed cell death receptor ligand 1 (PD-L1) for a subset of cancer patients. PD-1 sig
非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识 01 引言 近年来,以程序性死亡受体1(programmed death-1, PD-1)/PD配体1(PD ligand 1, PD-L1)免疫检查点抑制剂为主的免疫治疗在晚期肺癌中取得了突破性的进展,改变了该领域的治疗格局,为患者带来了更多生存获益。虽然对于免疫治疗适宜人群筛选和疗效预测的生物...
近日,来自德国CatalYm公司的Eugen Leo与西班牙纳瓦拉大学的Ignacio Melero共同在Nature期刊发表题为Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours(中和GDF-15能够克服实体肿瘤中抗PD-1和抗PD-L1治疗的耐药性) 的文章。研究报告了GDF-15阻断抗体Visugromab与抗PD-1联合治...
+1e b +df+(a) cells a+b+-cells of the indicating cell types. The red dotted lines represent the cut-off threshold for determining PD-L1+and PD-L1−cells.c-e, Volcano plots of DEGs between PD-L1+and PD-L1−Tom+cells in the indicated samples. The DEGs were identified by an FD...
PD-1 inhibitors with chemotherapy improved OS (HR 0.84, 0.77–0.92), PFS (HR 0.80, 0.75–0.85), and objective response rate (ORR) (odds ratio (OR) 2.55, 1.20–5.28) compared to PD-1 inhibitors as monotherapy. In contrast, PD-L1 inhibitors plus chemotherapy showed no significant ...